Browsing Tag
Arvinas Inc.
3 posts
Arvinas wins first FDA-approved PROTAC as ARVN stock tests investor patience
PROTAC drugs finally have FDA validation. Arvinas now faces the harder question: can VEPPANU become a commercial oncology asset?
What’s going on at Olema Oncology? CFO + COO Hans Bishop exits suddenly
Olema Oncology CFO and COO Hans Bishop has stepped down ahead of OP-1250 trial milestones. Find out what this means for investors and pipeline strategy.
Arvinas reports robust phase 1 signals for ARV-102 LRRK2 degrader at MDS 2025, pointing to meaningful target knockdown and brain penetration
Find out how Arvinas’ ARV-102 delivered strong Phase 1 LRRK2 knockdown and brain exposure at MDS 2025—and what it could mean for Parkinson’s trials next.